von Willebrand disease Medical Services in China

Von Willebrand disease (VWD) is the most common inherited bleeding disorder worldwide, affecting approximately 1% of the general population. It results from quantitative or qualitative defects in von Willebrand factor (VWF), a large multimeric glycoprotein essential for platelet adhesion to damaged vascular subendothelium and for stabilizing coagulation factor VIII (FVIII) in circulation. VWF mediates primary hemostasis by bridging platelets to exposed collagen at injury sites and acts as a carrier protein that protects FVIII from premature proteolysis—thus linking primary and secondary hemostasis. Pathogenically, VWD arises from mutations in the VWF gene on chromosome 12p13.3, leading to three major types: Type 1 (partial quantitative deficiency, ~75% of cases), Type 2 (qualitative defects with multiple subtypes—2A, 2B, 2M, 2N), and Type 3 (near-complete absence, rare but most severe). Inheritance is predominantly autosomal dominant for Types 1 and 2, while Type 3 follows autosomal recessive patterns. Epidemiologically, VWD affects all ethnic groups equally; however, diagnosis remains significantly under-recognized—especially in mild cases—due to variable expressivity, nonspecific symptoms, and lack of standardized global screening protocols. Prevalence estimates range from 0.6% to 1.3%, though only ~0.01% are clinically diagnosed, reflecting substantial diagnostic delay and undertreatment. Key risk factors include family history of mucocutaneous bleeding, consanguinity (particularly for Type 3), and female sex—menstruating individuals face heightened risks of menorrhagia, iron-deficiency anemia, and obstetric complications including postpartum hemorrhage. Quality of life impact is profound yet often underestimated: recurrent epistaxis, prolonged bleeding after dental procedures or minor trauma, easy bruising, and gastrointestinal bleeding contribute to chronic fatigue, anxiety around physical activity or surgery, school or work absenteeism, and psychosocial distress. Women frequently report diminished sexual health due to fear of menstrual or postcoital bleeding. Children may experience delayed diagnosis due to misattribution of symptoms to trauma or behavioral issues. Without appropriate prophylaxis or on-demand therapy, patients face increased morbidity during surgeries, childbirth, or invasive procedures—and in rare cases, life-threatening hemorrhage. Importantly, VWD is not merely a 'mild' bleeding disorder; its clinical heterogeneity demands individualized assessment using comprehensive testing—including VWF antigen (VWF:Ag), ristocetin cofactor activity (VWF:RCo), FVIII activity, and multimer analysis—to guide precise classification and management.

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting approximately 1% of the general population. It results from quantitative or qualitative defects in von Willebrand factor (VWF), a large multimeric glycoprotein essential for primary hemostasis. VWF mediates platelet adhesion to exposed subendothelial collagen at sites of vascular injury and serves as a carrier protein that stabilizes and protects coagulation factor VIII (FVIII) from proteolytic degradation in circulation. Deficiency or dysfunction of VWF leads to impaired platelet plug formation and accelerated FVIII clearance, resulting in mucocutaneous bleeding—such as epistaxis, menorrhagia, gingival bleeding, and prolonged bleeding after surgery or trauma.

The primary cause of VWD is genetic mutation in the VWF gene located on chromosome 12p13.31. Over 1,000 distinct pathogenic variants have been identified, including missense, nonsense, splice-site, frameshift, and large deletions or duplications. These mutations disrupt VWF synthesis, intracellular processing, multimer assembly, secretion, or plasma survival. Type 1 VWD (70–80% of cases) is typically autosomal dominant and characterized by partial quantitative deficiency of functionally normal VWF. Type 2 VWD (15–20%) involves qualitative defects and is further subclassified into 2A (impaired multimer assembly/secretion), 2B (gain-of-function leading to spontaneous platelet binding and clearance), 2M (reduced platelet binding without multimer loss), and 2N (impaired FVIII binding). Type 3 VWD (<5% of cases) represents near-complete absence of VWF and is usually autosomal recessive, often due to homozygous or compound heterozygous null mutations.

Genetic factors are central to VWD pathogenesis. Family history is a major determinant: first-degree relatives of affected individuals have up to a 50% risk in autosomal dominant forms (Types 1 and 2) and 25% risk in autosomal recessive Type 3. Penetrance is incomplete and variable, particularly in Type 1, contributing to underdiagnosis. Modifier genes—including ABO blood group—significantly influence VWF levels; individuals with blood group O exhibit ~25% lower baseline VWF and FVIII compared to non-O groups, increasing diagnostic ambiguity and bleeding risk. Polymorphisms in genes regulating VWF clearance (e.g., CLEC4M, STAB2) and inflammation (e.g., IL6, TNFα) may also modulate phenotypic expression.

Environmental and physiological triggers can unmask or exacerbate bleeding in genetically predisposed individuals. Acute phase responses—including infections, inflammation, pregnancy, and strenuous exercise—transiently elevate VWF levels via endothelial activation, potentially masking mild deficiency. Conversely, stress-induced catecholamine surges may paradoxically trigger bleeding in Type 2B VWD by promoting platelet aggregation and subsequent thrombocytopenia. Hormonal fluctuations, especially estrogen withdrawal during menstruation or postpartum, correlate with increased mucosal bleeding. Medications constitute critical iatrogenic triggers: antiplatelet agents (e.g., aspirin, NSAIDs), anticoagulants (e.g., warfarin, DOACs), SSRIs (via platelet serotonin depletion), and fibrinolytics markedly increase bleeding risk. Desmopressin (DDAVP) is therapeutic in many Type 1 and select Type 2 cases but contraindicated in Type 2B due to risk of severe thrombocytopenia.

Acquired VWD (aVWD), though rare, accounts for ~2–3% of clinically diagnosed cases and must be distinguished from inherited forms. It arises secondary to lymphoproliferative disorders (e.g., monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia), myeloproliferative neoplasms (especially essential thrombocythemia), autoimmune conditions (e.g., systemic lupus erythematosus), cardiovascular diseases (e.g., left ventricular assist devices, aortic stenosis causing shear-induced VWF proteolysis), and certain medications (e.g., valproic acid, sulfinpyrazone). In these settings, autoantibodies against VWF, increased proteolysis by ADAMTS13 or other metalloproteinases, or adsorption of VWF onto abnormal cells or surfaces drives functional deficiency.

Risk factors for clinical severity include female sex (due to menorrhagia and childbirth-related hemorrhage), younger age at diagnosis (often linked to early-life bleeding episodes such as umbilical stump bleeding or circumcision hemorrhage), concomitant inherited platelet disorders (e.g., Glanzmann thrombasthenia), and comorbidities impairing hemostasis—such as liver disease (reducing VWF synthesis), renal failure (altering VWF metabolism), or hypothyroidism (decreasing VWF production). Socioeconomic and healthcare access barriers contribute to delayed diagnosis and inadequate prophylactic management, particularly in resource-limited settings. Accurate classification requires integrated assessment: VWF antigen (VWF:Ag), ristocetin cofactor activity (VWF:RCo), FVIII activity, VWF multimer analysis, and increasingly, genetic sequencing. Misclassification remains common, underscoring the need for specialized hematologic evaluation in the hematology department.

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting approximately 1% of the general population. It results from quantitative or qualitative defects in von Willebrand factor (VWF), a large multimeric glycoprotein essential for platelet adhesion to subendothelial collagen at sites of vascular injury and for stabilizing coagulation factor VIII (FVIII) in circulation. VWD is classified into three major types: Type 1 (partial quantitative deficiency; ~75% of cases), Type 2 (qualitative defects with multiple subtypes—2A, 2B, 2M, 2N), and Type 3 (near-complete absence of VWF and markedly reduced FVIII; <1% of cases). Clinical manifestations vary widely by type and severity, but all share a mucocutaneous bleeding phenotype.

Early symptoms typically emerge in childhood or adolescence and often precede formal diagnosis by years. In infants, prolonged bleeding after circumcision or umbilical cord separation may be the first clue. Toddlers may exhibit excessive bruising with minimal trauma, recurrent epistaxis starting before age 5, or prolonged bleeding following minor oral trauma (e.g., teething, dental procedures). Menarche in adolescent girls frequently unmasks the disorder, presenting as menorrhagia—defined as menstrual blood loss exceeding 80 mL per cycle, lasting >7 days, or associated with clots >2.5 cm, anemia, or impairment in daily activities. Early recognition is critical, as delayed diagnosis contributes to avoidable morbidity, including iron-deficiency anemia and unnecessary surgical interventions.

Typical symptoms reflect impaired primary hemostasis and are predominantly mucocutaneous. Epistaxis is the most frequent symptom, occurring in up to 90% of symptomatic individuals, often recurrent and bilateral, lasting >10 minutes and requiring local intervention. Easy bruising—spontaneous or disproportionate to trauma—is nearly universal, with bruises commonly large (>5 cm), palpable, and located on extensor surfaces or pressure points. Prolonged bleeding after minor cuts, venipuncture, or dental extractions is characteristic; post-extraction bleeding lasting >10–15 minutes or requiring sutures or cautery is highly suggestive. Gingival bleeding, particularly during brushing or flossing, is common. Gastrointestinal bleeding may manifest as chronic occult blood loss leading to iron deficiency or, less commonly, overt melena or hematemesis—especially in Type 2A and 2B, where abnormal VWF multimers predispose to angiodysplasia-related bleeding. In women of reproductive age, menorrhagia remains a hallmark, often accompanied by dysmenorrhea and premenstrual fatigue due to chronic anemia.

Accompanying symptoms include signs of chronic blood loss and compensatory mechanisms. Fatigue, pallor, dizziness, and exertional dyspnea frequently reflect iron-deficiency anemia secondary to recurrent bleeding. Patients may report headaches or cognitive fog attributable to anemia or chronic hypoxia. Joint bleeding (hemarthrosis) is rare in VWD and strongly suggests concomitant hemophilia A or severe Type 3 disease; its presence warrants urgent reassessment of FVIII levels and differential diagnosis. Some patients with Type 2B VWD experience transient thrombocytopenia and myalgias during stress or infection, related to enhanced platelet binding and clearance. Mild proteinuria has been reported in severe cases, possibly reflecting VWF-mediated endothelial interactions, though clinical nephropathy is not a feature.

Complications arise from both acute hemorrhage and long-term sequelae. Severe epistaxis can lead to airway compromise or transfusion-dependent anemia. Postpartum hemorrhage poses significant risk—particularly in Types 2B and 3—due to abrupt declines in VWF and FVIII post-delivery. Gastrointestinal bleeding complications include iron-deficiency anemia, transfusion dependence, endoscopic intervention-related bleeding, and rarely, hypovolemic shock. Chronic menorrhagia contributes to infertility evaluation delays, endometrial hyperplasia (from unopposed estrogen in anovulatory cycles), and reduced quality of life. Surgical complications—including excessive intraoperative bleeding, reoperation for hemostasis, and prolonged hospitalization—are well documented without perioperative VWF/FVIII replacement or desmopressin prophylaxis. In Type 3 VWD, spontaneous intracranial hemorrhage, although rare, carries high mortality and mandates lifelong prophylactic therapy in select cases.

Diagnosis requires integration of clinical history, screening assays, and confirmatory testing. Initial screening includes complete blood count (CBC) with platelet count (typically normal), prothrombin time (PT; normal), activated partial thromboplastin time (aPTT; variably prolonged—often normal in Type 1, prolonged in Types 2N and 3), and fibrinogen (normal). Specific VWD testing comprises: (1) VWF antigen (VWF:Ag), quantifying total VWF protein; (2) VWF ristocetin cofactor activity (VWF:RCo), measuring functional capacity to support platelet binding; (3) Factor VIII coagulant activity (FVIII:C); and (4) VWF multimer analysis (gold standard for Type 2 subclassification). Ratio of VWF:RCo/VWF:Ag <0.6–0.7 supports qualitative defect (Type 2). Collagen-binding assay (VWF:CB) and next-generation sequencing for VWF gene variants may be employed in complex cases. Testing should be performed off hormonal therapy, non-steroidal anti-inflammatory drugs (NSAIDs), and acute-phase states, as VWF is an acute-phase reactant.

Differential diagnosis is essential to avoid misclassification. Immune thrombocytopenia (ITP) presents with isolated thrombocytopenia and petechiae—but normal PT/aPTT and absence of mucocutaneous bleeding triggers. Hemophilia A mimics Type 2N or 3 VWD clinically but shows discordantly low FVIII:C with preserved VWF:Ag and VWF:RCo. Platelet function disorders (e.g., Glanzmann thrombasthenia, Bernard-Soulier syndrome) demonstrate abnormal platelet aggregation studies and often thrombocytopenia (Bernard-Soulier) or absent GPIIb/IIIa (thrombasthenia). Acquired VWD—associated with lymphoproliferative disorders, cardiovascular malformations (e.g., aortic stenosis), or autoimmune conditions—typically occurs in older adults with no family history and may show inhibitory antibodies or proteolytic VWF degradation. Uremic bleeding, liver disease, and NSAID-induced gastropathy must also be excluded via renal/liver function tests and medication review. Finally, heavy menstrual bleeding due to structural gynecologic pathology (e.g., fibroids, adenomyosis) or endocrine dysfunction (e.g., thyroid disease, polycystic ovary syndrome) requires concurrent gynecologic evaluation.

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting approximately 1% of the global population. It results from quantitative or qualitative defects in von Willebrand factor (VWF), a multimeric glycoprotein essential for platelet adhesion to subendothelial collagen and for stabilizing coagulation factor VIII (FVIII) in circulation. VWD is classified into three major types: Type 1 (partial quantitative deficiency, ~75% of cases), Type 2 (qualitative abnormalities with multiple subtypes—2A, 2B, 2M, 2N), and Type 3 (near-complete absence of VWF and markedly reduced FVIII, <1% of normal, most severe). Management is individualized based on type, severity, bleeding phenotype, and clinical context—including surgery, trauma, menstruation, or pregnancy.

Conservative treatment forms the cornerstone of VWD management, particularly for mild Type 1 disease. This includes avoidance of antiplatelet agents (e.g., aspirin, NSAIDs, clopidogrel), use of soft-bristled toothbrushes and dental floss alternatives to minimize gingival trauma, and prompt local measures for minor bleeding—such as direct pressure, nasal packing for epistaxis, and topical antifibrinolytics (e.g., tranexamic acid mouthwash). Patients are advised to maintain optimal hemostatic conditions through hydration, avoidance of vigorous physical activities associated with high injury risk (e.g., contact sports), and pre-emptive counseling before invasive procedures. Comprehensive patient education—delivered by hematologists and specialized nurses—is critical: patients must understand their diagnosis, recognize early signs of abnormal bleeding (e.g., prolonged menses >7 days, menorrhagia requiring >5 pads/tampons daily, postpartum hemorrhage, spontaneous joint or muscle bleeds), and carry medical identification. Regular follow-up every 6–12 months enables reassessment of bleeding score, laboratory parameters (VWF:Ag, VWF:RCo, FVIII:C), and psychosocial impact.

Pharmacologic therapy is stratified by VWD type and clinical scenario. Desmopressin (DDAVP), a synthetic vasopressin analog, remains first-line for responsive Type 1 and select Type 2A/2M patients. It stimulates endothelial release of stored VWF and FVIII, typically increasing levels 2–5-fold within 30–90 minutes; effects last 4–6 hours. Intravenous, subcutaneous, or intranasal formulations are used—though intranasal dosing may be less reliable in children <6 years or obese adults. DDAVP responsiveness must be confirmed via formal challenge testing prior to therapeutic use, especially before surgery. For DDAVP-unresponsive patients—including all Type 3, most Type 2B (risk of thrombocytopenia), and Type 2N (FVIII-binding defect)—plasma-derived VWF/FVIII concentrates (e.g., Humate-P®, Wilate®, Vonvendi®) are indicated. These products contain physiologically multimeric VWF and varying ratios of VWF:RCo to FVIII:C, enabling targeted correction of both primary hemostasis and intrinsic coagulation. Recombinant VWF (e.g., Vonvendi®) offers viral safety advantages and consistent pharmacokinetics but lacks ultra-large multimers in some preparations. Antifibrinolytic agents—tranexamic acid and epsilon-aminocaproic acid—are adjunctive therapies that inhibit plasmin-mediated clot lysis; they are especially effective for mucosal bleeding (menorrhagia, oral, gastrointestinal) and are often combined with replacement therapy perioperatively. Hormonal therapy (combined oral contraceptives or levonorgestrel-releasing intrauterine systems) is standard for gynecologic management of menorrhagia in reproductive-age women with VWD.

Surgical treatment is not curative but refers to procedural interventions requiring meticulous hemostatic planning. All elective surgeries—including dental extractions, tonsillectomy, orthopedic procedures, and cesarean delivery—mandate multidisciplinary coordination between hematologists, anesthesiologists, surgeons, and obstetricians. Preoperative assessment includes bleeding history, baseline VWF/FVIII assays, and DDAVP trial if appropriate. Perioperative protocols involve prophylactic VWF/FVIII concentrate infusion (targeting VWF:RCo ≥50–100 IU/dL and FVIII:C ≥80–100 IU/dL pre-incision, maintained for 3–10 days depending on wound vascularity), concomitant antifibrinolytics, and avoidance of tourniquets or electrocautery where possible. Minimally invasive techniques (e.g., laparoscopic cholecystectomy, hysteroscopic endometrial ablation) are preferred when feasible. In rare refractory cases—such as life-threatening hemorrhage unresponsive to conventional therapy—recombinant activated factor VII (rFVIIa) may be considered off-label, though evidence remains limited and thrombotic risk warrants caution.

Treatment advantages in China reflect rapid advancements in infrastructure, regulatory frameworks, and clinical expertise. Since 2018, China’s National Reimbursement Drug List (NRDL) has included plasma-derived VWF/FVIII concentrates and tranexamic acid, significantly improving accessibility and affordability. Major tertiary hospitals—especially those affiliated with Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—host accredited Hemophilia Treatment Centers (HTCs) with integrated multidisciplinary teams, real-time coagulation monitoring, and 24/7 on-call support. Domestic manufacturing of high-purity, solvent-detergent treated VWF concentrates (e.g., Shenzhen Kexing Biopharma’s product) ensures stable supply chains and reduces import dependency. Furthermore, China’s national VWD registry (launched 2021) facilitates epidemiologic research, genotype–phenotype correlation studies, and personalized dosing algorithms. Telehematology platforms now enable remote consultations and home infusion training across provinces, bridging urban–rural disparities. Clinical trials of novel extended-half-life VWF products and gene therapy vectors are actively recruiting in China, positioning the country at the forefront of next-generation therapeutics.

Recovery and long-term management emphasize sustained hemostatic protection and quality-of-life optimization. Post-procedure, patients require serial VWF/FVIII level monitoring (typically at 2, 6, 24, and 72 hours post-infusion), clinical assessment for bleeding recurrence or thrombosis, and gradual tapering of replacement therapy per protocol. Physical rehabilitation should commence only after hemostasis is confirmed—early mobilization is encouraged for surgical patients, but weight-bearing restrictions apply following orthopedic interventions. Psychosocial recovery includes counseling for anxiety related to bleeding episodes, fertility planning, and transition care for adolescents moving to adult hematology services. Annual screening for iron deficiency anemia (via ferritin and hemoglobin), liver/kidney function, and inhibitor development (rare but reported in Type 3) is recommended. Vaccination against hepatitis A and B is strongly advised given frequent exposure to plasma-derived products. Finally, genetic counseling and cascade testing of first-degree relatives ensure early diagnosis and preemptive management—critical for preventing complications such as chronic anemia, arthropathy, or postpartum hemorrhage. With comprehensive, individualized care, most individuals with VWD achieve near-normal life expectancy and functional capacity.